Amsterdam-based CRO Clinquest Group has acquired a stake in Enceladus Pharmaceuticals, the Netherlands-based developer of the inflammatory disorder treatment Nanocort—the product is in phase II trials. Clinquest also gathered a group of additional investment groups to back Enceladus as it brings more products to market.
“The participation of Clinquest in our activities allows us to complete the phase IIa clinical proof-of-concept trial with Nanocort that is currently ongoing in The Netherlands. Therefore this means a major boost to our clinical development track,” said Bart Metselaar, founder and chief executive officer of Enceladus.
Clinquest said it believed in Enceladus’ development pipeline and in the future of Nanocort.
“By entering in this risk-sharing arrangement, we are able to support the further development of Nanocort and the entire liposomal development platform most efficiently,” said Cees Wortel, chief executive officer of Clinquest Group.